TEL AVIV, Israel, May 12, 2011 /PRNewswire/ -- InspireMD, Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), the developer of the MGuard™ mesh protective stent system, is happy to announce that MGuard is now available in India. MGuard, InspireMD's flagship product is India's first mesh-based coronary stent system and received a very warm welcome by the local cardiology community.
InspireMD will distribute the MGuard stent through KTPL, one of the leading suppliers of high-tech medical equipment in India. KTPL has already closed an initial order for the MGuard stent in India.
"Indians have one of the highest mortality and morbidity rates from Coronary artery disease (CAD) as compared to other ethnic groups and we are confident that the MGuard mesh-based coronary stent system  will become a very valuable new tool in the Indian cath labs, in which AMI patients are the vast majority," stated Asher Holzer, PhD President of InspireMD. "For the past two years, MGuard has met with much success in Europe and in South America. India possesses highly qualified interventional cardiologists and well-equipped hospitals, and I have full confidence that the country's cardiologists will welcome this new solution to distal embolization, one of the most common side effects in PCI procedures during AMI. We are also very glad to be teaming up with Kirloskar Technologies, a most capable partner and distributor of well known international manufacturers of high tech medical equipment in India. The initial order demonstrates the viability of this market and Kirloskar's commitment to making the MGuard a success in India."
Prof. Yaron Almagor from the Jesselson Heart Center, Shaare Zedek Medical Center, Jerusalem, was recently invited to India to present the MGuard technology.
"We have had good experience with MGuard in preventing dista